Library›Substances and pharmacology›Cytochrome P450 System Inhibition and Induction

Cytochrome P450 System Inhibition and Induction

Cytochrome P450 System: Inhibition, Induction, and Metabolic Activation provides an exhaustive biochemical guide to the primary enzymatic superfamily responsible for drug metabolism, xenobiotic clearance, and botanical bioactivation. Cytochrome P450 (CYP450) enzymes govern first-pass intestinal and hepatic clearance, determine the systemic bioavailability of pharmaceuticals and botanical actives, and dictate whether co-administered compounds produce clinical toxicity or therapeutic failure.

This article details the catalytic monooxygenase mechanism, major clinical isoforms, competitive versus mechanism-based suicide inhibition, nuclear receptor transcriptional induction, the critical divergence between prodrugs and active drugs, and the cannabinoid-CYP interface.

Catalytic biochemistry of the CYP450 superfamily

CYP450 enzymes are membrane-bound hemoproteins anchored to the cytosolic surface of the smooth endoplasmic reticulum in hepatocytes and intestinal enterocytes:

<code>

[ Substrate: R-H ] + O2 + NADPH + H⁺

│

▼ CYP450 (Heme Iron Catalysis)

[ Product: R-OH ] + H2O + NADP⁺

</code>

The monooxygenase cycle

1. Substrate binding: The lipophilic drug molecule ($R\text{-}H$) enters the hydrophobic active pocket and coordinates near the central heme iron ($Fe^{3+}$).

2. First electron transfer: NADPH-cytochrome P450 reductase transfers an electron to reduce the iron from ferric ($Fe^{3+}$) to ferrous ($Fe^{2+}$).

3. Oxygen activation: Molecular triplet oxygen ($O_2$) binds the ferrous iron. A second electron transfer forms a transient peroxo intermediate, which is protonated to release water ($H_2O$), generating a highly reactive ferryl-oxo radical cation ($\text{Compound I}, [Fe^{IV}=O]^{\bullet+}$).

4. Hydrogen abstraction and rebound: The ferryl oxygen abstracts a hydrogen atom from the substrate, forming a transient substrate radical, which immediately recombines ("oxygen rebound") to produce a hydroxylated, polar metabolite ($R\text{-}OH$).

Major clinical isoforms

Five distinct CYP families handle over 90% of all prescription drugs and psychoactive natural products:

{| class="wikitable"

! Isoform !! Relative liver abundance !! Primary substrates !! Potent inhibitors !! Potent inducers

| CYP3A4 / 3A5 || ~30% (Handles >50% of all drugs) || Fentanyl, statins, benzodiazepines, ketamine, THC-OH, macrolides || Grapefruit (bergamottin), piperine, ketoconazole, ritonavir, CBD || St. John's Wort (hyperforin), rifampin, carbamazepine, phenytoin

| CYP2D6 || ~2–4% (High phenotypic variation) || Codeine, tramadol, dextromethorphan, SSRIs, tricyclics, plant allylbenzenes || Fluoxetine, paroxetine, bupropion, piperine, quinidine || Not typically inducible (genetically regulated)

| CYP1A2 || ~13% || Caffeine, theophylline, melatonin, olanzapine, tacrine || Fluvoxamine, ciprofloxacin || Polycyclic aromatic hydrocarbons (smoking cannabis/tobacco), cruciferous vegetables

| CYP2C9 || ~20% || Δ9-THC (conversion to 11-OH-THC), warfarin, phenytoin, NSAIDs || CBD, fluconazole, amiodarone, sulfamethoxazole || Rifampin, St. John's Wort

| CYP2C19 || ~7% || Clopidogrel (prodrug), omeprazole, diazepam, escitalopram || CBD, fluconazole, fluvoxamine, omeprazole || Rifampin, carbamazepine

Mechanisms of enzyme inhibition

Inhibition occurs when a co-administered substance suppresses the catalytic turnover of an enzyme, sharply raising or lowering circulating drug levels:

<code>

[ INHIBITION MODES ]

│

┌─────────────────────────┴─────────────────────────┐

▼ ▼

[ Competitive / Reversible ] [ Mechanism-Based (MBI / Suicide) ]

• Competes for heme pocket • Substrate metabolically converted

• Rapid onset, concentration-dependent into reactive electrophilic radical

• Dissipates as inhibitor clears • Covalently destroys heme / apoprotein

• Requires de novo protein synthesis (days)

</code>

1. Competitive reversible inhibition

The inhibitor binds non-covalently within the active catalytic site, competing directly with the substrate.
Increases the apparent Michaelis constant ($K_m$) without altering maximum velocity ($V_{max}$).
Onset is rapid, and enzymatic activity recovers immediately once the inhibitor is cleared or displaced by high substrate concentrations.

2. Mechanism-Based Inactivation (MBI / "Suicide Inhibition")

The inhibitor acts as a "pseudosubstrate." The CYP enzyme attempts to metabolize the molecule, but the reaction generates an unstable, reactive electrophilic intermediate.
This reactive species attacks and forms an irreversible covalent bond with the catalytic heme iron or adjacent apoprotein amino acid residues, permanently destroying catalytic activity:

: <code>CYP + Prodrug/Inhibitor ──► [Reactive Carbene/Radical] ──► Covalent Inactivation</code>

Grapefruit Furanocoumarins (Bergamottin and 6',7'-dihydroxybergamottin): Irreversibly destroy intestinal enterocyte CYP3A4. Recovery requires 48 to 72 hours for the gut epithelium to biosynthesize new CYP3A4 proteins.
Piperine (Black Pepper): Exhibits mechanism-based inactivation of human CYP3A4 and CYP2D6 alongside reversible inhibition, accounting for dramatic systemic exposure surges of co-administered botanicals.

Mechanisms of enzyme induction

Enzyme induction is the process by which a compound increases the physical concentration of CYP450 enzymes by upregulating gene transcription:

Nuclear receptors: Xenobiotics bind to intracellular nuclear receptors, including the Pregnane X Receptor (PXR), the Constitutive Androstane Receptor (CAR), or the Aryl Hydrocarbon Receptor (AhR).
Transcriptional activation: Upon ligand binding, the receptor forms a heterodimer with the retinoid X receptor (RXR), translocates to the nucleus, and binds response elements in the promoter region of specific CYP genes, accelerating mRNA transcription.
Kinetics: Unlike rapid inhibition, induction is a slow biological process taking several days to weeks to reach maximal expression, and persisting for days after the inducer is discontinued while excess enzymes degrade.
St. John's Wort (Hypericum perforatum): The active constituent hyperforin is one of the most potent natural agonists of human PXR, driving massive induction of CYP3A4 and P-glycoprotein. Co-ingestion slashes circulating blood levels of oral contraceptives, cyclosporine, antiretrovirals, and statins, causing widespread clinical failures.
Combustion smoke: Inhaling polycyclic aromatic hydrocarbons (PAHs) from combusted cannabis or tobacco smoke activates AhR, heavily inducing CYP1A2. Smokers metabolize caffeine roughly 50% faster than non-smokers.

The critical divergence: prodrugs vs. active drugs

Whether enzyme modulation causes dangerous toxicity or therapeutic failure depends entirely on whether the target compound is an active drug or a metabolic prodrug:

{| class="wikitable"

! Molecule type !! Standard status !! Effect of CYP INHIBITION !! Effect of CYP INDUCTION

| Active Drug (e.g., Fentanyl, Warfarin, Alprazolam) || Active as ingested; CYP enzymes inactivate and clear it. || Toxicity / Overdose: Clearance blocked; drug accumulates to toxic plasma levels. || Subtherapeutic Failure: Cleared too rapidly; drug fails to reach clinical threshold.

| Metabolic Prodrug (e.g., Codeine, Clopidogrel, Psilocybin) || Inactive/less active as ingested; CYP enzymes convert it into active metabolite. || Therapeutic Failure: Conversion blocked; parent prodrug cleared without releasing active drug. || Toxicity / Rapid Surge: Conversion accelerated; sudden burst of active metabolite.

Codeine Example: Codeine is an inactive prodrug that requires CYP2D6 to undergo O-demethylation into active morphine. If a patient takes a strong CYP2D6 inhibitor (such as fluoxetine or piperine), codeine cannot convert to morphine and produces zero analgesia. Conversely, a genetic "ultra-rapid metabolizer" converts codeine to morphine rapidly, risking fatal respiratory depression at standard therapeutic doses.

Cannabinoids and the CYP450 matrix

Phytocannabinoids are both major substrates and potent modulators of hepatic CYP enzymes:

1. CBD as a master inhibitor

Cannabidiol (CBD) is a potent, clinically documented competitive inhibitor of CYP3A4, CYP2C19, and to a lesser degree CYP2D6.
High clinical doses of oral CBD (such as Epidiolex) significantly raise serum levels of the anti-epileptic clobazam (via CYP2C19 inhibition) and elevate blood levels of warfarin, requiring clinical dosage reductions.

2. THC metabolic activation

Ingested Δ9-THC undergoes extensive first-pass hepatic metabolism:

: <code>Δ9-THC ──(CYP2C9 / CYP3A4)──► 11-Hydroxy-Δ9-THC (11-OH-THC) ──(CYP2C9)──► 11-Nor-9-carboxy-THC</code>

11-OH-THC: Significantly more potent than Δ9-THC at crossing the blood-brain barrier and possesses higher intrinsic efficacy at the CB1 receptor, explaining why oral cannabis edibles produce a markedly heavier, longer-lasting, and more psychedelic experience than inhaled cannabis.

Filed under Substances and pharmacology Organic chemistry and synthesis